Esposito Susanna, Marchisio Paola, Bosis Samantha, Lambertini Lara, Claut Laura, Faelli Nadia, Bianchi Ciro, Colombo Giorgio L, Principi Nicola
Institute of Pediatrics, Pediatric Department 1, University of Milan, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Commenda 9, 20122 Milano, Italy.
Vaccine. 2006 Jan 30;24(5):629-35. doi: 10.1016/j.vaccine.2005.08.054. Epub 2005 Aug 25.
This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age+/-S.D.: 3.22+/-2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.
本文报告了有关2至5岁健康儿童接种流感疫苗所带来的净经济成本节约的数据，这对于确定儿科流感疫苗使用的最佳建议可能会有所帮助。共有303名之前未接种过疫苗的2至5岁健康儿童（163名男性；平均年龄±标准差：3.22±2.43岁）被前瞻性、盲法随机分为2:1的比例，分别接受两剂灭活三价病毒体配方亚单位流感疫苗（Inflexal V，瑞士伯尔尼Berna Biotech公司）或不接种疫苗。结果表明，2至5岁健康儿童接种流感疫苗可大幅减少儿童自身及其家庭的流感样疾病及相关成本。然而，在建议对这组人群进行普遍接种之前，可能需要开展规模更大、持续时间更长且跨越多个季节的研究。
